News
NVAX
8.70
+0.23%
0.02
Peering Into Novavax's Recent Short Interest
Benzinga · 1d ago
Novavax’s Strategic Partnerships and Pipeline Developments Drive Buy Rating with Promising Long-term Growth Potential
TipRanks · 1d ago
Novavax says Australia cancels delivery of some Covid-19 doses
TipRanks · 3d ago
NOVAVAX INC - ON DEC 12, ENTERED AMENDMENT 5 TO ADVANCED PURCHASE AGREEMENT WITH COMMONWEALTH OF AUSTRALIA
Reuters · 3d ago
NOVAVAX- AGREED TO UPDATED DELIVERY SCHEDULE FOR POTENTIAL DELIVERY OF COVID-19 VACCINE/FUTURE VARIANT COVID-19 VACCINE THROUGH END OF 2029
Reuters · 3d ago
NOVAVAX- ACKNOWLEDGED COMMONWEALTH CANCELLATION OF DELIVERING CERTAIN DOSES OF CO’S COVID-19 VACCINE SCHEDULED FOR DELIVERY BETWEEN Q4 2023 & Q4 2025
Reuters · 3d ago
CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Benzinga · 3d ago
CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Benzinga · 3d ago
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Simply Wall St · 4d ago
Notable Monday Option Activity: AVAV, NKE, NVAX
NASDAQ · 5d ago
Unusually active option classes on open December 16th
TipRanks · 5d ago
Weekly Report: what happened at NVAX last week (1209-1213)?
Weekly Report · 5d ago
Novavax advances growth strategy through partnership with Sanofi
TipRanks · 12/13 13:10
NOVAVAX ADVANCES CORPORATE GROWTH STRATEGY THROUGH SANOFI PARTNERSHIP, INCLUDING ACHIEVEMENT OF FIRST $50 MILLION MILESTONE
Reuters · 12/13 13:00
Novavax Nabs $50M From First Sanofi Partnership Milestone: Retail Optimism Climbs
Barchart · 12/13 09:12
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
NASDAQ · 12/11 15:25
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
NASDAQ · 12/11 12:50
Novavax Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Dow Jones · 12/10 17:22
HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target
Benzinga · 12/10 17:12
Novavax Gains Buy Rating Amid Vaccine Development Advancements and Strong Valuation Model
TipRanks · 12/10 14:45
More
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax Inc through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.